ZA200300258B - New amidino derivatives and their use as thrombin inhibitors. - Google Patents
New amidino derivatives and their use as thrombin inhibitors. Download PDFInfo
- Publication number
- ZA200300258B ZA200300258B ZA200300258A ZA200300258A ZA200300258B ZA 200300258 B ZA200300258 B ZA 200300258B ZA 200300258 A ZA200300258 A ZA 200300258A ZA 200300258 A ZA200300258 A ZA 200300258A ZA 200300258 B ZA200300258 B ZA 200300258B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- compounds
- pharmaceutically acceptable
- acceptable derivative
- Prior art date
Links
- 229940122388 Thrombin inhibitor Drugs 0.000 title description 13
- 239000003868 thrombin inhibitor Substances 0.000 title description 13
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 241
- 239000000203 mixture Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 34
- 229960004072 thrombin Drugs 0.000 claims description 32
- 108090000190 Thrombin Proteins 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 24
- -1 methoxy, methyl Chemical group 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 208000007536 Thrombosis Diseases 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 13
- 238000010168 coupling process Methods 0.000 claims description 13
- 238000005859 coupling reaction Methods 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 230000005764 inhibitory process Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 229940127219 anticoagulant drug Drugs 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
- 238000010511 deprotection reaction Methods 0.000 claims description 7
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 201000005665 thrombophilia Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 claims description 2
- 229940008406 diethyl sulfate Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 239000000243 solution Substances 0.000 description 38
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- 239000003112 inhibitor Substances 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 150000003863 ammonium salts Chemical class 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 150000001409 amidines Chemical group 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000001715 carotid artery Anatomy 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002399 angioplasty Methods 0.000 description 4
- 229940095076 benzaldehyde Drugs 0.000 description 4
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005345 coagulation Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 125000001151 peptidyl group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 4
- IADUEWIQBXOCDZ-UHFFFAOYSA-N (2S)-azetidine-2-carboxylic acid Natural products OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 3
- LKBQUSJJIYIBDP-UHFFFAOYSA-N (3-chloro-5-nitrophenyl)methanol Chemical compound OCC1=CC(Cl)=CC([N+]([O-])=O)=C1 LKBQUSJJIYIBDP-UHFFFAOYSA-N 0.000 description 3
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical group OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 208000001435 Thromboembolism Diseases 0.000 description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- GPHYIQCSMDYRGJ-UHFFFAOYSA-N (3,5-dinitrophenyl)methanol Chemical compound OCC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 GPHYIQCSMDYRGJ-UHFFFAOYSA-N 0.000 description 2
- QOQKOVFSUNXURX-UHFFFAOYSA-N (3-amino-5-nitrophenyl)methanol Chemical compound NC1=CC(CO)=CC([N+]([O-])=O)=C1 QOQKOVFSUNXURX-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 206010002388 Angina unstable Diseases 0.000 description 2
- 108010058207 Anistreplase Proteins 0.000 description 2
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 2
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001504495 Erithacus Species 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000012317 TBTU Substances 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940007550 benzyl acetate Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 229960003766 thrombin (human) Drugs 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 108010036927 trypsin-like serine protease Proteins 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- BLGQROIGCHBMQP-UHFFFAOYSA-N 2-(aminomethyl)benzenecarboximidamide Chemical class NCC1=CC=CC=C1C(N)=N BLGQROIGCHBMQP-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- VYWYYJYRVSBHJQ-UHFFFAOYSA-N 3,5-dinitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 VYWYYJYRVSBHJQ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 206010056867 Activated protein C resistance Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102000004032 Heparin Cofactor II Human genes 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical group 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 238000013130 cardiovascular surgery Methods 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- RUMFZCKCISCDMG-UHFFFAOYSA-N o-(2-methylpropyl)hydroxylamine Chemical compound CC(C)CON RUMFZCKCISCDMG-UHFFFAOYSA-N 0.000 description 1
- TVPSRTVMZGECAT-UHFFFAOYSA-N o-(pyridin-3-ylmethyl)hydroxylamine Chemical compound NOCC1=CC=CN=C1 TVPSRTVMZGECAT-UHFFFAOYSA-N 0.000 description 1
- NAROWIGYQNQXHL-UHFFFAOYSA-N o-[(2-bromophenyl)methyl]hydroxylamine Chemical compound NOCC1=CC=CC=C1Br NAROWIGYQNQXHL-UHFFFAOYSA-N 0.000 description 1
- KBXVIQKLRHKPEJ-UHFFFAOYSA-N o-[(3-methoxyphenyl)methyl]hydroxylamine Chemical compound COC1=CC=CC(CON)=C1 KBXVIQKLRHKPEJ-UHFFFAOYSA-N 0.000 description 1
- MLWXTMVARHZBPA-UHFFFAOYSA-N o-[(4-methylphenyl)methyl]hydroxylamine Chemical compound CC1=CC=C(CON)C=C1 MLWXTMVARHZBPA-UHFFFAOYSA-N 0.000 description 1
- NBPJAYNNXNWURB-UHFFFAOYSA-N o-[(5-chlorothiadiazol-4-yl)methyl]hydroxylamine Chemical compound NOCC=1N=NSC=1Cl NBPJAYNNXNWURB-UHFFFAOYSA-N 0.000 description 1
- KMTWTTUPPAJQMM-UHFFFAOYSA-N o-[(5-methyl-1,2-oxazol-3-yl)methyl]hydroxylamine Chemical compound CC1=CC(CON)=NO1 KMTWTTUPPAJQMM-UHFFFAOYSA-N 0.000 description 1
- DVKKNCOZHBDJHQ-UHFFFAOYSA-N o-[2-[3-(trifluoromethyl)phenoxy]ethyl]hydroxylamine Chemical compound NOCCOC1=CC=CC(C(F)(F)F)=C1 DVKKNCOZHBDJHQ-UHFFFAOYSA-N 0.000 description 1
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
- WHFMUIWBJFYAGJ-UHFFFAOYSA-N o-cyclobutylhydroxylamine Chemical compound NOC1CCC1 WHFMUIWBJFYAGJ-UHFFFAOYSA-N 0.000 description 1
- KYKNGOPXRHUCHC-UHFFFAOYSA-N o-cyclohexylhydroxylamine Chemical compound NOC1CCCCC1 KYKNGOPXRHUCHC-UHFFFAOYSA-N 0.000 description 1
- AQFWNELGMODZGC-UHFFFAOYSA-N o-ethylhydroxylamine Chemical compound CCON AQFWNELGMODZGC-UHFFFAOYSA-N 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical class NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- YFMZQCCTZUJXEB-UHFFFAOYSA-N tris(methylsulfanyl)methane Chemical compound CSC(SC)SC YFMZQCCTZUJXEB-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
°
NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN
INHIBITORS
: Field of the Invention . This invention relates to novel pharmaceutically useful compounds, in - ~ particular compounds that are, and/or compounds that are metabolised to compounds which are, competitive: inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.
Blood coagulation is the key process involved in both haemostasis (i.e. the prevention of blood loss from a damaged vessel) and thrombosis (i.e. the - formation of a blood clot in a blood vessel, sometimes leading to vessel obstruction). ~ Coagulation is the result of a complex series of enzymatic reactions. One of : the ultimate steps in this series of reactions is the conversion of the proenzyme prothrombin to the active enzyme thrombin.
Thrombin is known to play a central role in coagulation. It activates platelets, leading to platelet aggregation, converts fibrinogen into fibrin monomers, which polymerise spontaneously into fibrin polymers, and activates factor XIII, which in turn crosslinks the polymers to form ' ~ insoluble fibrin. Furthermore, thrombin activates factor V and factor VIL. ] leading to a “positive feedback” generation of thrombin from prothrombin.
By inhibiting the aggregation of platelets and the formation and crosslinking of fibrin, effective inhibitors of thrombin would be expected to exhibit
° 3 Co antithrombotic activity. In addition, antithrombotic activity would be expected to be enhanced by effective inhibition of the positive feedback : mechanism. -
Prior Art ~The early development of low molecular weight inhibitors of thrombin has been described by Claesson in Blood Coagul. Fibrinol. (1994) 5, 411.
Blomback er al (in J. Clin. Lab. Invest. 24, suppl. 107, 59, (1969)) reported thrombin inhibitors based on the amino acid sequence situated around the cleavage site for the fibrinogen Aa chain. Of the amino acid sequences discussed, these authors suggested the tripeptide. sequence Phe-Val-Arg (P9-P2-P1, hereinafter referred to as the P3-P2-P1 sequence) would be the most effective inhibitor. .
Thrombin inhibitors based on dipeptidyl derivatives with an o,®-aminoalkyl guanidine in the P1-position are known from US Patent N° 4,346,078 and
International Patent Application WO 93/11152. Similar, structurally related, dipeptidyl derivatives have also been reported. For example
International Patent Application WO 94/29336 ‘discloses compounds with, for example, aminomethyl benzamidines, cyclic aminoalkyl amidines and cyclic aminoalkyl guanidines in the Pl-position (International Patent
Application WO 97/23499 discloses prodrugs of certain of these compounds); European Patent Application 0 648 780, discloses compounds with, for example, cyclic aminoalkyl guanidines in the P1-position.. oo .
Thrombin inhibitors based on peptidyl derivatives, also having cyclic aminoalkyl guanidines (e.g. either 3- or 4- aminomethyl-1-amidino- :
°o piperidine) in the P1-position are known from European Patent Applications 0468 231, 0 559 046 and 0 641 779.
Thrombin inhibitors based on tripeptidyl derivatives with arginine aldehyde . 5 in the P1-position were first disclosed in European Patent Application 0 185 : 390. Co
More recently, arginine aldehyde-based peptidyl derivatives, modified in the P3-position, have been reported. For example, International Patent
Application WO 93/18060 discloses hydroxy acids, European Patent
Application 0 526 877 des-amino acids, and European Patent Application 0 542 525 O-methyl mandelic acids in the P3-position.
Inhibitors of serine proteases (e.g. thrombin) based on electrophilic ketones in the Pl-position are also known. For example, European Patent
Application 0 195 212 discloses peptidyl a-keto esters and amides,
European Patent Application 0 362 002 fluoroalkylamide ketones, European
Patent Application 0 364 344 q,B,6-triketocompounds, and European Patent
Application 0 530 167 a-alkoxy ketone derivatives of arginine in the P1- position. : _ Other, structurally different, inhibitors of trypsin-like serine proteases based on C-terminal boronic acid derivatives of arginine and isothiouronium analogues thereof are known from European Patent Application 0 293 881. . More recently, thrombin inhibitors based on peptidyl derivatives have been disclosed in European Patent Application 0 669.317 and International Patent
Applications WO 95/35309, WO 95/23609, WO 96/25426, WO 97/02284,
WO 97/46577, WO 96/32110," WO 96/31504, WO 96/03374, WO 98/06740, WO 97/49404, WO 98/57932, WO 99/29664 and WO 00/35869.
® | )
In particular WO 97/02284 and WO 00/42059 disclose thrombin inhibitors with substituted mandelic acids in the P3 position.
However, there remains a need for effective inhibitors of trypsin-like serine . 5 proteases, such as thrombin. There is also a need for compounds which have a favourable pharmacokinetic profile (e.g. low clearance) and are’ selective in inhibiting thrombin over other serine proteases, in particular ~ those involved in haemostatis. Compounds which exhibit competitive inhibitory activity towards thrombin would be expected to be especially useful as anticoagulants and therefore in the therapeutic treatment of thrombosis and related disorders.
According to the invention there is provided compounds of formula I,
EV
HO [ H
N H
NH, oO oo Cl NH
R : . wherein
R! represents C(O)CH; or C,; alkyl; and
Y represents -CH;- or -(CH,),-, and pharmaceutically-acceptable derivatives thereof.
The term “pharmaceutically-acceptable derivatives” includes inter alia pharmaceutically-acceptable salts (e.g. acid addition salts).
/ : “ Cs ® :
Preferred compounds of formula I include those in which: : R' represents C(O)CH;, methyl or ethyl; .
Y represents -CH,-. oo - 5
Particularly preferred compounds of formula I include - Ph(3-CI)(5-NHMe)-CH(OH)C(O)-Aze-Pab;
Ph(3-CI)(5-NHACc)-CH(OH)C(O)-Aze-Pab. :
Abbreviations are listed at the end of this specification.
Compounds of formula I may be made in accordance with techniques well known to those skilled in the art, for example as described hereinafter.
According to a further aspect of the invention there is provided a process for the preparation of a compound of formula I, which comprises: (i) the coupling of a compound of formula II 0 :
OH i cl NH .
Ly :
R wherein R! is as hereinbefore defined, with a compound of formula III,
® © —Y NH "NN N Hl . Vs
H NH, : 8) : wherein Y is as hereinbefore defined, for example in the presence of a . coupling agent (e.g. oxalyl chloride in DMF, EDC, DCC, HBTU, HATU,
PyBOP or TBTU), an appropriate base (e.g. pyridine, DMAP, TEA, 2,4,6- collidine or DIPEA) and a suitable organic solvent (e.g. dichloromethane, acetonitrile, EtOAc or DMF); (11) the coupling of a compound of formula Iv,
Oo v :
HO [
N OH \Y o cl NH
Po oo
R1 : wherein R' and Y are as hereinbefore defined, with para- amidinobenzylamine, for example under conditions as described in step (i) above; or (iii) deprotection of a protected derivative of a compound of formula I under
Compounds of formula I may be prepared by way of deprotection of a corresponding compound of formula XV, as defined hereinafter, which deprotection comprises removal of the group C(O)OR%, in which R* is as defined hereinafter, from the compound of formula XV, for example under
® conditions known to those skilled in the art (e.g. by reacting with QF or
TFA (e.g. as described hereinafter)).
F urther, compounds of formula I may be prepared by way of deprotection of a ) 5 corresponding compound of formula Ia, as defined hereinafter, in which R? represents OR? , wherein R? and R® are as defined heremafter, for example by hydrogenation in the presence of a suitable catalyst (e.g. a supported metal catalyst such as Pd/C (e.g. 10% (w/w) Pd/C)) and an appropriate solvent (e.g. a lower (e.g. Cy) alkyl alcohol such as ethanol), and optionally in the presence of a suitable acid (e.g. acetic acid).
Compounds of formula II are available using known and/or standard techniques.
For example, compounds of formula II may be prepared by reaction of an aldehyde of formula V,
Os _H
Ci NH
L1
R : wherein R' is as hereinbefore defined with: . : . (a) a compound of formula VI, _—
R"CN vio
® 8 wherein R" represents H or (CH;);Si, for example at room, or elevated, temperature (e.g. below 100°C) in the presence of a suitable organic solvent (e.g. chloroform or methylene chloride) and, if necessary, in the presence of a suitable base (e.g. TEA) and/or a suitable catalyst ‘system (e.g. benzylammonium chloride or zinc iodide), followed by hydrolysis under conditions that are well known to those skilled in the art (e.g. as described - hereinafter); : : (b) NaCN or KCN, for example in the presence of NaHSO; and water, followed by hydrolysis; (© chloroform, for example at elevated temperature (e.g. above room temperature but below 100°C) in the presence of a suitable organic solvent (e.g. chloroform) and, if necessary, in the presence of a suitable catalyst system (e.g. benzylammonium chloride), followed by hydrolysis; : (d) a compound of formula VII, aay Sow : wherein M represents Mg or Li, followed by oxidative cleavage (eg. ozonolysis or osmium or ruthenium catalysed) under conditions which are : well known to those skilled in the art; or (e) tris(methylthio)methane under conditions which are well known to those . : skilled in the art, followed by hydrolysis in the presence of e.g. HgO and
HBF, oo EE
°o g
Compounds of formula II may alternatively be prepared from Ph(3-CI)(5-
NH,)-CH(OH)C(O)OH, for example as described hereinafter for compounds of formula II in which R represents C(O)CH; or methyl. ] 5 The enantiomeric forms of the compound of formula II (i.e. those compounds having different configurations of substituents about the C-atom a- to the COH | group) may be separated by an enantiospecific derivatisation step. This may be achieved, for example by an enzymatic process. Such enzymatic processes include, for example, transesterification of the a-OH group at between room and reflux temperature (e.g. at between 45 and 65°C) in the presence of a suitable enzyme (e.g. Lipase PS Amano), an appropriate ester (e.g. vinyl acetate) and a suitable solvent (e.g. methyl tert-butyl ether). The derivatised isomer may then be separated from the unreacted isomer by conventional separation techniques (e.g. chromatography). :
Groups added to compounds of formula II in such a derivatisation step may be removed either before any further reactions or at any later stage in the synthesis of compounds of formula I. The additional groups may be removed using conventional techniques (e.g. for esters of the a-OH group, hydrolysis under conditions known to those skilled in the art (e.g. at between room and reflux temperature in the presence of a suitable base (e.g.
NaOH) and .an appropriate solvent (e.g. MeOH, water or mixtures thereof))). 2s : ’ Compounds of formula IV may be prepared by coupling a compound of ~~ formula II as hereinbefore defined to a compound of formula VIII,
® | 0 —
N - VII wherein Y is as hereinbefore defined, for example under similar conditions . to those described herein for preparation of compounds of formula I.
Compounds of formula V are available using known and/or standard techniques. For example, they may be prepared by: (i) reduction of a compound of formula X,
Ox_OMe al NH 4 - 10 R wherein R' is as hereinbefore defined, or a protected derivative thereof, in the presence of a suitable reducing agent (e. g. DIBAL-H); or (ii) oxidation of a compound of formula XI,
OH : :
A ’
Ie NH lL
R .
® 11 wherein R! is as hereinbefore defined, or a protected derivative thereof, in the presence of a suitable oxidising agent (e.g. MnO, pyridinium chlorochromate or a combination of DMSO and oxalyl chloride).
Compounds of formulae III, VI, VII, VIII, X and XI are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from readily available starting materials using appropriate reagents and reaction conditions (e.g. as described hereinafter). : Compounds of formula I may be isolated from their reaction mixtures using conventional techniques.
In accordance with the present invention, pharmaceutically acceptable derivatives of compounds of formula I also include “protected” derivatives, and/or compounds that act as prodrugs, of compounds of formula I.
Compounds that may act as prodrugs of compounds of formula I that may be mentioned include compounds of formula Ia, ; 1 | N—R?2 & eves : : 5 NH, la : Oo cl NH oo oo 1 wherein R? represents OR or C(O)OR%
® | 12
R? represents H, Cy. alkyl, C,.; alkylaryl or Cy; alkyloxyaryl (the alkyl ~ parts of which latter two groups are optionally interrupted by one or more oxygen atoms, and the aryl parts of which latter two groups are optionally substituted by one or more substituents selected from halo, phenyl, methyl or methoxy, which latter three groups are also optionally substituted by one or more halo substituents); rR represents Co alkyl (which latter group is optionally interrupted by one or more oxygen atoms), or C,;; alkylaryl or Cy; alkyloxyaryl (the alkyl parts of which latter two groups are optionally interrupted by one or more oxygen atoms, and the aryl parts of which latter two groups are optionally substituted by one or more substituents selected from halo, phenyl, methyl or methoxy, which latter three groups are also optionally substituted by one or more halo substituents); and
R' and Y are as hereinbefore defined, and pharmaceutically-acceptable derivatives thereof.
The term “phammaceutically-acceptable derivatives” of compounds of formula Ia includes pharmaceutically-acceptable salts (e.g. acid addition salts). | Co E
Alkyloxyaryl groups that R? and R* may represent comprise an alkyl and an aryl group linked by way of an oxygen atom. Alkylaryl and alkyloxyaryl groups are linked to the rest of the molecule via the alkyl part of those groups, which alkyl parts may (if there is a sufficient number (i.e. three) of carbon atoms) be branched-chain. The aryl parts of alkylaryl and alkyloxyaryl. groups which R? and R* may represent include carbocyclic and . heterocyclic aromatic (heteroaryl) groups, such as phenyl, naphthyl, pyridinyl, oxazolyl, isoxazolyl, thiadiazolyl (e.g. 1,2,3-thiadiazolyl), indolyl and benzofuranyl and the like. : :
® : 13 _ Alkyl groups which R® and R* may represent may be straight-chain or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms, be branched-chain and/or cyclic. Further, when there is a sufficient number ) (i.e. a minimum of four) of carbon atoms, such alkyl groups may also be part cyclic/acyclic. Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms, be ‘unsaturated.
Halo groups with which R® and R* may be substituted include fluoro, chloro, bromo and iodo.
When R® represents C(O)OR*, preferred R* groups include: : (a) linear, branched or cyclic C4 alkyl, for example C4. cycloalkyl; (b) Ci, alkylaryl groups, such as benzyl, optionally substituted as indicated hereinbefore.
Preferred compounds of formula Ia include those in which R? represents
OR’. +20 When R? represents OR’, preferred R> groups include: (@ HH; oo : . (b) unsubstituted, linear, branched or cyclic C;5 (e.g. Cy.6) alkyl, such as linear Cy; alkyl (e.g. methyl, ethyl or i-propyl), branched Cs alkyl (e.g. i-butyl) or cyclic Cy; alkyl (e.g. cyclobutyl or cyclohexyl); (c) C,.; alkyloxyphenyl (e.g. C, alkyloxyphenyl), the phenyl group of 3 oo which is optionally substituted by one or more substituents as = indicated hereinbefore (e.g. trifluoromethyl); (d Ci, alkylaryl (e.g. methylaryl), wherein the aryl group is phenyl, pyridinyl, isoxazolyl or thiadiazolyl, which latter four groups are
PN 14 optionally substituted by one or more substituents as indicated hereinbefore (e.g. methoxy, methyl, bromo and/or chloro).
Preferred compounds of formula Ia include those in which R? represents
OR’ and R® represents: (i) linear or cyclic (as appropriate), Cy (e.g. C14) alkyl, such as methyl, ethyl, i-propyl or cyclohexyl; or (ii) methylaryl, wherein the aryl group is phenyl or isoxazolyl, which latter two groups are optionally substituted in the aryl part by one substituent selected from methoxy, methyl and bromo (e.g. 4 methylbenzyl, 3-methoxybenzyl, 2-bromobenzyl or 5-methyl-3- ‘isoxazolyl). :
Compounds of formula Ia may be prepared by one or more of the following . 15° methods: (a) the coupling of a compound of formula II as hereinbefore defined with a compound of formula XII, = N—R2 ap rt Xl
H NH, ..
Oo wherein Y and R? are as hereinbefore defined, for example under similar conditions to those described hereinbefore for synthesis of compounds of formula; oo Co Co (b) the coupling of a compound of formula IV, as hereinbefore defined, with a compound of formula X11,
° : i
Xl wr NH, wherein R? is as hereinbefore defined, for example under similar conditions ~ + 5 to those described hereinbefore for synthesis compounds of formula I; (c) for compounds of formula Ia in which R? represents OH, reaction of a corresponding compound of formula XIV, 0 v
HO. [ . N N Lr XIV 0]
Cl NH
Ls
R : : wherein R! and Y are as hereinbefore defined, with hydroxylamine, for example under conditions known to those skilled in the art; : (d) for compounds of formula Ia in which R? represents OR, reaction of a protected derivative of a corresponding compound of formula I which is, for example, a compound of formula XV,
® 0 e JL
HO 1 ) oF ps yea" XV 0 oo
Cc NH | - i wherein R* represents, for example, -CH,CH,-Si(CH3); or benzyl, and R! and Y are as hereinbefore defined, or a tautomer thereof, with a compound : 5 of formula XVI,
R’ONH, | XVI wherein R® is as hereinbefore defined, or an acid addition salt thereof, for example at between room and reflux temperature in the presence of an appropriate organic solvent (e.g. THF, CH;CN, DMF or DMSO), followed by removal of the -C(O)OR” group under conditions known to those skilled in the art (e.g. by reacting with QF or TFA (e.g. as described hereinafter)); (e) for compounds of formula Ia in which R? represents COOR*, reaction of a corresponding compound of formula I, as hereinbefore defined, with a compound of formula XVII,
L'COOR* : XVII wherein L! represents a suitable leaving group, such as halo, and R* 1s as N hereinbefore defined, for example at or around room temperature in the . presence of suitable base (e.g. NaOH, for example in aqueous solution) and an appropriate organic solvent (e.g. methylene chloride); or
® : (f) for compounds of formula Ia in which R represents OCH; or OCH,CHj, reaction of a corresponding compound of formula Ia in which R? represents ) OH with dimethylsulfate or diethylsulfate, respectively, for example in the presence of a suitable base (e.g. an alkali metal hydroxide such as KOH (for example in aqueous solution at e.g. 50 wt.%)) and an appropriate catalyst (e.g. a quaternary ammonium halide such as benzyltrimethylammonium chloride (for example in CH,Cl, or THF solution at e.g. 10 wt.%)).
Compounds of formula XIV and XV may be prepared by the coupling of a corresponding compound of formula II to, respectively, a compound of formula XVIII,
Y .
H Lr o | Co wherein Y 1s as hereinbefore defined, or a compound of formula XIX, 0
Mr —Y N” “Oo
AN ¥ [ XIX
NH, oO . 20 wherein Y and R* are as hereinbefore defined, for example in each case under similar conditions to those described hereinbefore for synthesis compounds of formula I.
® 18
Compounds of formula XIV and XV may alternatively be prepared by coupling of a corresponding compound of formula IV to, respectively, para- cyanobenzylamine, or a compound of formula XX,
Q .
HN | 9 or XX
S NH, wherein R* is as hereinbefore defined, for example in each case under similar conditions to those described hereinbefore for synthesis compounds of formula I.
Co : :
Compounds of formula XV may altematively be prepared by reaction of a corresponding compound of formula XIV with hydroxylamine under - conditions known to those skilled in the art, followed by: (i) reduction of the resulting hydroxyamidine under conditions known to those skilled in the art (e.g. by catalytic hydrogenation); and then (1) reaction of the resulting compound of formula I with a compound corresponding to a compound of formula XVII in which, in place of R*, the group R* is present, in which R* is as hereinbefore defined, for example under conditions described above in respect of the preparation of compounds of formula Ia.
Compounds of formulae XII, XVIII and XIX may be prepared by the coupling of a corresponding compound of formula VIII, as hereinbefore . defined, to, respectively, a compound of formula XIII as hereinbefore defined, para-cyanobenzylamine, or a compound of formula XX as ’ hereinbefore defined, for example in each case under similar conditions to those described hereinbefore for synthesis of compounds of formula I.
PY 19
Compounds of formulae XIII, XVI, XVII and XX are either commercially available, are known in the literature, or may be obtained either by analogy ) with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from readily available starting materials using appropriate reagents and reaction conditions (e.g. as : * described hereinafter).
Compounds of formula Ia may be isolated from their reaction mixtures using conventional techniques.
Compounds of formula I and Ia, as defined above, and derivatives of either, are referred to hereinafter as “the compounds of the invention”.
The compounds of the invention may exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.
Particular tautomeric forms that may be mentioned include those connected with the position of the double bond in the amidine functionality in a compound of formula Ia, and the position of the substituent R2.
Compounds of the invention also contain two or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the . compounds using. conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by ) reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, for example with a homochiral acid followed by separation
® : 20 of the diastereomeric derivatives by conventional means (e.g. HPLC, chromatography over silica). All stereoisomers are included within the scope of the invention.
Compounds of the invention in which the ] . y * A >) : : Oo fragment is in the S-configuration are preferred.
Compounds of the invention in which the 0
PY oe NH ©
R1 fragment is in the R-configuration are preferred.
The wavy lines on the bonds in the above fragments signify the bond positions of the fragments. © 20 Thus, particularly preferred compounds of the invention include
Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(0)-(S)Aze-Pab; and
Ph(3-C1)(5-NHAc)-(R)CH(OH)C(0)-(S)Aze-Pab.
® It will be appreciated by those skilled in the art that in the processes described above and hereinafter the functional groups of intermediate compounds may need to be protected by protecting groups.
Functional groups that it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl groups (e.g. t-butyldimethylsilyl, z-butyldiphenylsilyl or trimethylsilyl) and tetrahydropyranyl. Suitable protecting groups for carboxylic acid include C4 alkyl or benzyl esters. Suitable protecting groups for amino and amidino include #-butyloxycarbonyl, benzyloxycarbonyl or 2-trimethylsilylethoxycarbonyl (Teoc). Amidino - mitrogens may also be protected by hydroxy or alkoxy groups, and may be . either mono- or diprotected.
The protection and deprotection of functional groups may take place before or after coupling, or before or after any other reaction in the "abovementioned schemes.
Protecting groups may be removed in accordance with techniques that are well known to those skilled in the art and as described hereinafter. .
Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative, and, on some occasions, more convenient, manner, the individual process steps mentioned hereinbefore may be performed in a different order, and/or the individual reactions may be . . performed at a different stage in the overall route (i.e. substituents may be added to and/or chemical transformations performed upon, different ) intermediates to those mentioned hereinbefore in conjunction with a particular reaction). This may negate, or render necessary, the need for oo protecting groups.
® . 22
The type of chemistry involved will dictate the need, and type, of protecting + groups as well as the sequence for accomplishing the synthesis.
The use of protecting groups is fully described in “Protective Groups in
Organic Chemistry”, edited by J W F McOmie, Plenum Press (1973), and ~ “Protective Groups in Organic Synthesis”, 3 edition, T W Greene & P G
M Wutz, Wiley-Interscience (1999).
Protected derivatives of compounds of the invention may be converted chemically to compounds of the invention using standard deprotection techniques (e.g. hydrogenation). The skilled person will also appreciate that certain compounds of formula Ia may also be referred to as being “protected derivatives” of compounds of formula I. :
Some of the intermediates referred to hereinbefore are novel.
According to a further aspect of the invention there is thus provided: (a) a compound of formula II as hereinbefore defined or a protected derivative thereof; (b) a compound of formula IV, as hereinbefore defined, or a protected derivative thereof; (c) a compound of formula XIV, as hereinbefore defined, or a protected derivative thereof; and (d) a compound of formula XV, as hereinbefore defined, or a protected derivative thereof,
Preferred compounds of formula I include Ph(3-Cl)(5-NHMe)-
CH(OH)C(O)OH and Ph(3-Cl)(5-NHAc)-CH(OH)C(O)OH. Preferred : compounds of formula III include Ph(3-Cl)(5-NHMe)-CH(OH)C(O)-Aze-
OH and Ph(3-CI)(5-NHAc)-CH(OH)C(O)-Aze-OH. Preferred compounds : of formula XV include Ph(3-CI)(5-NHMe)-CH(OH)C(O)-Aze-Pab(Teoc) and Ph(3-CI)(5-NHAc)-CH(OH)C(O)-Aze-Pab(Teoc).
® | 2 . Medical and Pharmaceutical Use
Compounds of the invention may possess pharmacological activity as such. } 5 Compounds of the invention that may possess such activity include, but are not limited to, compounds of formula I. - : However, other compounds of the invention (including compounds of formula Ia) may not possess such activity, but may be administered parenterally or orally, and may thereafier be metabolised in the body to form compounds that are pharmacologically active (including, but not . limited to, corresponding compounds of formula I). Such compounds (which also includes compounds that may possess some pharmacological activity, but that activity is appreciably lower than that of the “active” compounds to which they are metabolised), may therefore be described as “prodrugs” of the active compounds.
Thus, the compounds of the invention are useful because they possess pharmacological activity and/or are metabolised in the body following oral or parenteral administration to form compounds which possess pharmacological activity. The compounds of the invention are therefore indicated as pharmaceuticals.
According to a further aspect of the invention there is thus provided the compounds of the invention for use as pharmaceuticals.
In particular, compounds of the invention are potent inhibitors of thrombin ~ either as such and/or (e.g. in the case of prodrugs), are metabolised following administration to form potent inhibitors of thrombin, for example as may be demonstrated in the tests described below.
PS 24
By “prodrug of a thrombin inhibitor”, we include compounds that form (i.e. are metabolised to) a thrombin inhibitor, in an experimentally-detectable amount, and within a predetermined time (e.g. about 1 hour), following oral or parenteral administration (see, for example, Test E below) or, alternatively, following incubation in the presence of liver microsomes (see, for example, Test G below).
The compounds of the invention are thus expected to be useful in those: conditions where inhibition of thrombin is required, and/or conditions where anticoagulant therapy is indicated, including the following: ‘The treatment and/or prophylaxis of thrombosis and hypercoagulability in blood and/or tissues of animals including man.” It is known that hypercoagulability may lead to thrombo-embolic diseases. Conditions associated with hypercoagulability and thrombo-embolic diseases which may be mentioned include inherited or acquired activated protein C resistance, such as the factor V-mutation (factor V Leiden), and inherited or acquired deficiencies in antithrombin III, protein C, protein S, heparin cofactor II. Other conditions known to be associated with hypercoagulability and thrombo-embolic disease include circulating antiphospholipid antibodies (Lupus anticoagulant), homocysteinemi, heparin induced thrombocytopenia and defects in fibrinolysis, as well as _ coagulation syndromes (e.g. disseminated intravascular coagulation (DIC)) and vascular injury in general (e.g. due to surgery). : The treatment of conditions where there is an undesirable excess of thrombin without signs of hypercoagulability, for example in neurodegenerative diseases such as Alzheimer’s disease.
Particular disease states which may be mentioned include the therapeutic and/or prophylactic treatment of venous thrombosis (e.g. DVT) and pulmonary embolism, arterial thrombosis (e.g. in myocardial infarction, unstable angina, thrombosis-based stroke and . peripheral arterial thrombosis), and systemic embolism usually from the atrium during atrial fibrillation or from the left ventricle after transmural myocardial infarction, “or caused by congestive heart failure; prophylaxis of re-occlusion (ie. thrombosis) after thrombolysis, percutaneous trans-luminal angioplasty ~ (PTA) and coronary bypass operations; the prevention of re-thrombosis after microsurgery and vascular surgery in general.
Further indications include the therapeutic and/or prophylactic treatment of disseminated intravascular coagulation caused by bacteria, multiple trauma, intoxication or any other mechanism; anticoagulant treatment when blood is in contact with foreign surfaces in the body such as vascular grafts, vascular stents, vascular catheters, mechanical and biological prosthetic valves or any other medical device; and anticoagulant treatment when blood is in contact with medical devices outside the body such as during cardiovascular surgery using a heart-lung machine or in haemodialysis; the therapeutic and/or prophylactic treatment of idiopathic and adult respiratory distress syndrome, pulmonary fibrosis following treatment with radiation or chemotherapy, septic shock, septicemia, inflammatory responses, which include, but are not limited to, edema, acute or chronic atherosclerosis such as coronary arterial disease and the formation of atherosclerotic plaques, cerebral arterial disease, cerebral infarction, cerebral thrombosis, cerebral . embolism, peripheral arterial disease, ischaemia, angina (including unstable angina), reperfusion damage, restenosis after percutaneous trans-luminal ) angioplasty (PTA) and coronary artery bypass surgery.
Compounds of the invention that inhibit trypsin and/or thrombin may also be useful in the treatment of pancreatitis.
The compounds of the invention are thus indicated both in the therapeutic and/or prophylactic treatment of these conditions.
According to a further aspect of the present invention, there is provided a method of treatment of a condition where mhibition of thrombin is required which method comprises administration of a therapeutically effective amount of a compound of the invention to a person suffering from, or susceptible to, such a condition.
The compounds of the invention will normally be administered orally, mntravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, by any other parenteral route or via inhalation, in the form of pharmaceutical preparations comprising active compound either as a free base, or a pharmaceutically acceptable non-toxic organic or inorganic acid addition salt, or other derivative, in a pharmaceutically acceptable dosage form. }
Depending upon the disorder and patient to be treated and the route of administration, the compositions may be administered at varying doses.
The compounds of | the invention may also be combined and/or co- administered with any antithrombotic agent with a different mechanism of action, such as the antiplatelet agents acetylsalicylic acid, ticlopidine, : clopidogrel, thromboxane receptor and/or synthetase inhibitors, fibrinogen receptor antagonists, prostacyclin mimetics and phosphodiesterase inhibitors and ADP-receptor (P,T) antagonists and inhibitors of carboxypeptidase U (CPU).
® *
The compounds of the invention may further be combined and/or co- administered with thrombolytics such as tissue plasminogen activator } (natural, recombinant or modified), streptokinase, urokinase, prourokinase, anisoylated plasminogen-streptokinase activator complex (APSAC), animal salivary gland plasminogen activators, and the like, in the treatment of thrombotic diseases, in particular myocardial infarction.
According to a further aspect of the invention there is thus provided a pharmaceutical formulation including a compound of the invention, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.
Suitable daily doses of the compounds of the invention in therapeutic treatment of humans are about 0.001-100 mg/kg body weight at peroral administration and 0.001-50 mg/kg body weight at parenteral administration.
The compounds of the invention have the advantage that they may be more efficacious, be less toxic, be longer acting, have a broader range of activity, be more potent, produce fewer side effects, be more easily absorbed, and/or have a better pharmacokinetic profile (e.g. lower clearance), than, or have other useful pharmacological, physical, or chemical, properties over, compounds known in the prior art.
Biological Tests . i The following test procedures may be employed. :
) i 28
Test A
Determination of Thrombin Clotting Time (TT)
The inhibitor solution (25 pL) is incubated with plasma (25 pL) for three minutes. Human thrombin (T 6769; Sigma Chem. Co or Hematologic
Technologies) in buffer solution, pH 7.4 (25 pL, 4.0 NIH units/mL), is then added and the clotting time measured in an automatic device (KC 10;
Amelung).
The thrombin clotting time (TT) is expressed as absolute values (seconds) as well as the ratio of TT without inhibitor (TT) to TT with inhibitor (TT).
The latter ratios (range 1-0) are plotted against the concentration of inhibitor (log transformed) and fitted to sigmoidal dose-response curves according to : the equation : y = a/[1H(x/1Cs0)°] where: a = maximum range, i.e. 1; s = slope of the dose-response curve; and
ICsp = the concentration of inhibitor that doubles the clotting time. The calculations are processed on a PC using the software program GraFit
Version 3, setting equation equal to: Start at 0, define end = 1 (Erithacus
Software, Robin Leatherbarrow, Imperial College of Science, London, UK).
Determination of Thrombin Inhibition with a Chromogenic, Robotic Assay
The thrombin inhibitor potency is measured with a chromogenic substrate method, in a Plato 3300 robotic microplate processor (Rosys AG, CH-8634 Hombrechtikon, Switzerland), using 96-well, half volume microtitre plates (Costar, Cambridge, MA, USA; Cat No 3690). Stock solutions of test . substance in DMSO (72 pL), 0.1 - 1 mmol/L, are diluted serially 1:3 (24 + 48 pL) with DMSO to obtain ten different concentrations, which are analysed as samples in the assay. 2 pL of test sample is diluted with 124 pl. assay buffer, 12 pl. of chromogenic’ substrate solution (S-2366,
® 29
Chromogenix, Mélndal, Sweden) in assay buffer and finally 12 pL of a- thrombin solution (Human o-thrombin, Sigma Chemical Co. or
Hematologic Technologies) in assay buffer, are added, and the samples mixed. The final assay concentrations are: test substance 0.00068 - 13.3 pmol/L, S-2366 0.30 mmol/L, a-thrombin 0.020 NIHU/mL.
The linear absorbance increment during 40 minutes incubation at 37°C is ‘used for calculation of percentage inhibition for the test samples, as compared to blanks without inhibitor. The ICsp-robotic value, corresponding to the inhibitor concentration which causes 50% inhibition of the thrombin activity, is calculated from a log concentration vs. % inhibition : curve. :
Test C
Determination of the Inhibition Constant K; for Human Thrombin
K;-determinations are made using a chromogenic substrate method, performed at 37°C on a Cobas Bio centrifugal analyser (Roche, Basel,
Switzerland). Residual enzyme activity after incubation of human a-thrombin with various concentrations of test compound is determined at three different substrate concentrations, and is measured as the change in optical absorbance at 405 nm.
Test compound solutions (100 pL; normally in buffer or saline containing "BSA 10 g/L) are mixed with 200 pl. of human o-thrombin (Sigma
Chemical Co) in assay buffer (0.05 mol/L Tris-HCI pH 7.4, ionic strength 0.15 adjusted with NaCl) containing BSA (10 g/L), and analysed as samples ‘ -- in the Cobas Bio. A 60 pL sample, together with 20 pL of water, is added - to 320 pL of the substrate S-2238 (Chromogenix AB, Mélndal, Sweden) in assay buffer, and the absorbance change (AA/min) is monitored. The final concentrations of S-2238 are 16, 24 and 50 pmol/L and of thrombin 0.125
NIH U/mL.
® 30 .
The steady state reaction rate is used to construct Dixon plots, i.e. diagrams of inhibitor concentration vs. 1/(AA/min). For reversible, competitive inhibitors, the data points for the different substrate concentrations typically form straight lines which intercept at x = -K. 5 .
Test D
Determination of Activated Partial Thromboplastin Time (APTT)
APTT is determined in pooled normal human citrated plasma with the reagent PTT Automated 5 manufactured by Stago. The inhibitors are added to the plasma (10 pL inhibitor solution to 90 pL plasma) and incubated with the APTT reagent for 3 minutes followed by the addition of 100 pL of calcium chloride solution (0.025 M) and APTT is determined by use of the coagulation analyser KC10 (Amelung) according to the instructions of the reagent producer.
The clotting time is expressed as absolute values (seconds) as well as the ratio of APTT without inhibitor (APTT,) to APTT with inhibitor (APTT)).
The latter ratios (range 1-0) are plotted against the concentration of inhibitor (log transformed) and fitted to sigmoidal dose-response curves according to : the equation y = a/[1+(x/ICsp)’] where: a = maximum range, i.e. 1; s = slope of the dose-response curve; and
ICs, = the concentration of inhibitor that doubles the clotting time. The : calculations are processed on a PC using the software program GraFit
Version 3, setting equation equal to: Start at 0, define end = 1 (Erithacus
Software, Robin Leatherbarrow, Imperial College of Science, London, UK).
IC5pAPTT is defined as the concentration of inhibitor in human plasma that doubled the Activated Partial Thromboplastin Time.
® 31
Determination of Thrombin Time ex vivo
The inhibition of thrombin after oral or parenteral administration of the ’ compounds of the invention, dissolved in ethanol:Solutol™ water (5:5:90), is examined in conscious rats which, one or two days prior to the experiment, are equipped with a catheter for blood sampling from the carotid artery. On the experimental day blood samples are withdrawn at fixed times after the administration of the compound into plastic tubes containing 1 part sodium citrate solution (0.13 mol per L) and 9 parts of blood. The tubes are centrifuged to obtain platelet poor plasma. 50 pL of plasma samples are precipitated with 100 pL of cold acetonitrile.
The samples are centrifuged for 10 minutes at 4000 rpm. 75 pL of the : supernatant is diluted with 75 pL of 0.2% formic acid. 10 pL volumes of the resulting solutions are analysed by LC-MS/MS and the concentrations of thrombin inhibitor are determined using standard curves. :
Determination of Plasma Clearance in Rat
Plasma clearance was estimated in male Sprague Dawley rats. The compound was dissolved in water and administered as a subcutaneous bolus injection at a dose of 4 pmol/kg. Blood samples were collected at frequent intervals up to 5 hours after drug administration. Blood samples were centrifuged and plasma was separated from the blood cells and transferred to vials containing citrate (10% final concentration). 50 pL of plasma samples are precipitated with 100 pL of cold acetonitrile. The samples are centrifuged for 10 minutes at 4000 rpm. 75 pL of the supernatant is diluted with 75 pL of 0.2% formic acid. 10 pL volumes of the resulting solutions are analysed by LC-MS/MS and the concentrations of thrombin inhibitor are determined using standard curves. The area under the plasma“
® | 32 concentration-time profile was estimated using the log/linear trapezoidal rule and extrapolated to infinite time. Plasma clearance (CL) of the compound was then determined as
CL=Dose/AUC
The values are reported in mL/min/kg.
Determination of in vitro Stability oo
Liver microsomes were prepared from Sprague-Dawley rats and human liver samples according to internal SOPs. The compounds were incubated at 37°C at a total microsome protein concentration of 3 mg/mL in a 0.05 : mol/L TRIS buffer at pH 7.4, in the presence of the cofactors NADH (2.5 mmol/L) and NADPH (0.8 mmol/L). The initial concentration of compound was 5 or 10 pmol/L. Samples were taken for analysis up to 60 minutes after the start of the incubation. The enzymatic activity in the collected sample was immediately stopped by adding 20% myristic acid at a volume corresponding to 3.3% of the total sample volume. The concentration of compound remaining (FINAL CONC) in the 60 min. sample was determined by means of LCMS using a sample collected at zero time as reference (START CONC). The % of degraded thrombin inhibitor was calculated as: 100% x [START CONC] - [FINAL CONC] ~ [starrconc]
TestH
Arterial Thrombosis Model .
Vessel damage was induced by applying ferric chloride (FeCls) topically to the carotid artery. Rats are anaesthetised with an intraperitoneal injection of sodium pentobarbital (80 mg/kg; Apoteksbolaget; Umed, Sweden), followed by continuous infusion (12 mg/kg/h) throughout the experiment.
) ' 33 . N
Rat body temperature was maintained at 38°C throughout the experiment by external heating. The experiment started with a 5 minutes control period.
Five minutes later, human '*’L-fibrinogen (80 kBq; IMS53; Amersham
International, Buckinghamshire, UK) was given intravenously and was used as a marker for the subsequent incorporation of fibrin(ogen) into the thrombus. The proximal end of the carotid artery segment was placed in a plastic tube (6 mm; Silastic®; Dow Corning, MI, USA) opened lengthways, containing FeCl;-soaked (2 pL; 55% w/w; Merck, Darmstadt, Germany) filter paper (diameter 3 mm; 1F; Munktell, Grycksbo, Sweden). The left carotid artery was exposed to FeCl; for 10 minutes and was then removed from the plastic tube and soaked in saline. Fifty minutes later, the carotid artery was removed and rinsed in saline. Reference blood samples were also taken for determination of blood 'I-activity, 10 minutes after the injection of '»I-fibrinogen, and at the end of the experiment. The '*I-activity in the reference blood samples and the vessel segment were measured in a gamma counter (1282 Compugamma; LKB Wallac Oy, Turku, Finland) on the . same day as the experiment was performed. The thrombus size was determined as the amount of **I-activity incorporated in the vessel segment in relation to the '*’I-activity in the blood (cpm/mg). : 20 .
The invention is illustrated by way of the following examples.
General Experimental Details
TLC was performed on silica gel.
Chiral HPLC analysis was performed using a 46. mm X 250 mm Chiralcel :
OD column with a 5 cm guard column. The column temperature was maintained at 35°C. A flow rate of 1.0 mL/min was used. A Gilson 115 oo
UV detector at 228 nm was used. The mobile phase consisted of hexanes,
® 34 ethanol and trifluroacetic acid and the appropriate ratios are listed for each compound. Typically, the product was dissolved in a minimal amount of ethanol and this was diluted with the mobile phase.
LC-MS/MS was performed using a HP-1100 instrument equipped with a
CTC-PAL injector and a 5 pum, 4x100 mm ThermoQuest, Hypersil BDS-
C18 column. An API-3000 (Sciex) MS detector was used. The flow rate was 1.2 ml/min and the mobile phase (gradient) consisted of 10-90% acetonitrile with 90-10% of 4 mM aq. ammonium acetate, both containing 0.2% formic acid. '"H NMR spectra were recorded using tetramethylsilane as the internal standard. *C NMR spectra were recorded using the listed deuterated solvents as the internal standard. ‘Melting points are uncorrected.
Example 1
Ph(3-Cl)(5-NHMe)-(R)YCH(OH)C(O)-(S)Aze-Pab (i) Ph(3-CI)(5-NHMe)-(R)CH(OH)C(0)OH . Method A:
A mixture of Ph(3-Cl)(5-NH,)-(R)CH(OH)C(O)OH (3.5 g, 16.8 mmol; see international patent application WO 00/42059) and formaldehyde (1.8 mL - of 37 wt% m H,0, 23.9 mmol) in EtOH (400 mL) was stirred at 25°C for. : 18 h. The solution was concentrated in vacuo to give a crushable foam that was combined with platinum(TV) oxide (0.35 g) in EtOH (400 mL) and stirred under a hydrogen atmosphere for 48 h. ‘The mixture was filtered through a pad of Celite® and the filter cake washed with EtOH. The
® 35
OIganics were concentrated in vacuo and flash chromatographed on silica gel eluting with CHCl;:MeOH:concentrated NH,OH (7:2.5:0.5) to afford 1.0 g (28%) of the ammonium salt of the sub-title compound as a crushable foam. The sub-title compound was obtained by flushing the corresponding i 5 ammonium salt through a pad of Amberlite® CG-50 with CH;CN:MeOH : (3:1). :
Method B:
A mixture of Ph(3-CI)(5-NH,)-(R)CH(OH)C(O)OH (8.67 g, 43.0 mmol; see international patent application WO 00/42059) and methyl iodide (6.10 g, 43.0 mmol) in CH3;CN (500 mL) and MeOH (100 mL) was heated to 50°C for 24 h. The solution was concentrated in vacuo and flash chromatographed on silica gel eluting with CHCl;:MeOH:concentrated . NH4OH (7:2.5:0.5) to afford 2.9 g (31%) of the ammonium salt of the sub- title compound as a solid. The sub-title compound was obtained by flushing the corresponding ammonium salt through a pad of Amberlite® CG-50 with
CH;CN:MeOH (3:1). | oo
Mp: 58-65°C
Rg=0.25 (6:3:1 CHCl3:MeOH:concentrated NH,OH) 'H NMR (300 MHz, CD;0D) § 6.68 (m, 1H), 6.61 (m, 1H), 6.50 (m, 1H), 4.98 (s, 1H), 2.75 (5, 3H). 3C NMR (75 MHz, CD;0D) 5 176.8, 153.4, 144.1, 136.7, 116.3, 113.2, 111.0,74.7, 31.3
APIMS:(M+1)=216m/z : HPLC Analysis: -97.2%, 97.9% ee, Chiralcel OD Column (90:10:0.5
Hex:EtOH:TFA mobile phase). [a]p® =-81.6° (c = 1.0, MeOH)
® : 36 (ii) Ph(3-C)(5-NHMe)-(R)CH(OH)C(0)-(S)Aze-Pab(Teoc)
To a mixture of Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(O)OH (0.21 g, 0.97 mmol; see step (1) above) and H-(S)Aze-Pab(Teoc) (0.38 g, 1.02 mmol, see international patent application WO 00/42059) in DMF (10 mL) at 0°C was added collidine (0.26 g, 2.13 mmol) and PyBOP (0.56 g, 1.07 mmol). The solution was stirred at 0°C for 2 h, warmed to 25°C, stirred for 18 h and then concentrated in vacuo. Extensive flash chromatography (3x) on silica gel eluting first with CHCl;:EtOH (9:1), then with CHCl5:EtOH (95:5), and finally with EtOAc:EtOH (20:1) gave 0.31 g (61%) of the sub-title compound as a crushable foam.
Mp: 93-98°C
R¢= 0.40 (9:1 CHCI;:EtOH) 'H NMR (300 MHz, CD;OD, mixture of rotamers) 7.82 (d, 2H, J = 9 Hz), 7.42 (d, 2H, J = 9 Hz), 6.66 (m, 1H), 6.48-6.59 (m, 2H), 5.13 and 4.78 (m, 1H), 5.02 (s, 1H) 3.96-4.58 (m, 6H), 2.76 (s, 3H), 2.05-2.75 (m, 2H), 1.05- © 1.13 (m, 2H), 0.07 (5, 9H)
API-MS: M + 1) =574 m/z (iii) Ph(3-CI)(5-NHMe)-(R)CH(OH)C(O)-(S)Aze-Pab
To an ice-cold solution of Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(O)-(S)Aze-
Pab(Teoc) (71 mg, 0.12 mmol, from step (ii) above) in methylene chloride (10 mL) was added TFA (1 mL), and the mixture was stirred at 0°C for 2h and 1h at rt, whereafter the resultant mixture was concentrated in vacuo.
The remainder was dissolved in water and freeze-dried, yielding 79 mg - (97%) of the title compound. N : oo . 'H NMR (500 MHz, CD;0D): (complex due to diastereomers/rotamers) § 7.74 (d, 2H), 7.52 (d, 2H); 7.03 (t, 0.25H, minor rotamer); 6.98 (t, 0.25H, minor rotamer); 6.96 (t, 0.75H, major rotamer); 6.93 (t, 0.25H, minor
® 37 rotamer); 6.89 (t, 0.25H, major rotamer); 6.84 (t, 0.25H, major rotamer); 5.22 (dd, 0.25H, minor rotamer); 5.12 (s, 0.75H, major rotamer); 5.10 (s, 0.25H, minor rotamer); 4.80 (dd, 0.75H, major rotamer); 4.58-4.44 (several peaks, 2H); 4.34 (m, 0.75H, major rotamer); 4.12-3.95 (several peaks, 1.25H); 2.87 (s, 0.75H, minor rotamer); 2.83 (s, 2.25H, major rotamer); 2.70 (m, 0.25H, minor rotamer); 2.53 (s, 0.75H, major rotamer); 2.27 (m, 0.75H, major rotamer); 2.15 (s, 0.25H, minor rotamer). *C NMR (100 MHz, CDCl): (carbonyl and/or amidine carbons) § 174.2; 173.6; 172.9; 168.1.
MS: (M+1)430 m/z
Example 2
Parallel synthesis of alkoxyamidines
This synthesis was performed in a 96-well Robbins block.
To a well containing an appropriate amount of O-substituted hydroxylamine (specified below) was added a solution of Ph(3-Cl)(5-NHMe)- (R)CH(OH)C(O)-(S)Aze-Pab(Teoc) (10 mg; 17 pmol; see Example 1(ii) above) in acetonitrile (1.0 mL). The block was sealed and the reaction mixture was rotated overnight in an oven at 60°C. After cooling and filtration, the solids were washed with acetonitrile (3 x 0.3 mL). The combined liquid fractions were concentrated in a vacuum centrifuge. The residue was partitioned between water (0.4 mL) and ethyl acetate (0.4 mL). . Following liquid-liquid extraction everything was filtered through a column of Hydromatrix™. After washing three times with ethyl acetate, the combined filtrates were concentrated in a vacuum centrifuge. Deprotection was performed by addition of methylene chloride (0.1 mL) and : trifluoroacetic acid (0.3 mL). After stirring at room temperature for 3 h the solvents were removed in vacuo. The residue was partitioned between sodium hydrogencarbonate (0.5 mL of a saturated aqueous solution) and ethyl acetate (0.5 mL). After extraction, filtration through Hydromatrix™ : and concentration (vide infra), the residue was dissolved in isopropanol/water (7/3) (1 mL). About 2% of this solution was removed and diluted with isopropanol/water (7/3) (1 mL) for LC-MS analysis. After "removal of the solvents in vacuo the solid residue was transferred to a 96- well plate using acetonitrile and ethyl acetate to dissolve the compound.
The solvents were evaporated in a vacuum centrifuge to afford the following title compounds (all starting materials were commercially : available): : 2.1 Ph(3-CI)(5-NHMe)-(R)CH(OH)C(O)-(S)Aze-Pab( OCH,-3-isoxazole( 5-
Me))
Prepared using 3-[(aminooxy)methyl]-5-methylisoxazole x HCI (21 mg; 0.13 mmol). Yield: 4.66 mg (50%)
LC (254 mn) 100%
MS(m/z) 541 (M+1)* : 2.2 Ph(3-CI)(5-NHMe)-(R)CH(OH)C(0)~(S)Aze-Pab(OCH,-3-pyridine)
Prepared using 3-[(aminooxy)methyl]pyridine x 2HCI (17 mg; 86 pmol).
Yield: 7.56 mg (81%).
LC: 100% :
MS(m/z) 537 (M+1)* y 2.3 Ph(3-CI)(5-NHMe)-(R)YCH(OB)C(0)-(S)Aze-Pab(QiBu)
Prepared using O-isobutylhydroxylamine x HCI (13 mg; 104 pmol). Yield: 4.9 mg (56%).
LC: 100%
MS(m/z) 502 (M+1)*
® 39 2.4 Ph(3-CI)(5-NHMe)-(R)CH(OH)C(O)~(S)Aze-Pab(OEt)
Prepared using O-ethylhydroxylamine x HCI (13 mg; 133 pmol). Yield: ) 7.13 mg (86%).
LC:100%
MS(m/z) 474 M+1)* 2.5 Ph(3-CI)(5-NHMe)-(R)CH(OH)C(O)~(S) Aze-Pab(OBn)
Prepared using O-benzylhydroxylamine x HCI (18 mg; 113 pmol). Yield: 5.76 mg (62%).
LC: 100%
MS(m/z) 536 (M+1)" 2.6 Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(0)-(S)Aze-Pab(OcHexyl)
Prepared using O-cyclohexylhydroxylamine x HCl (12 mg; 79 pmol).
Yield: 7.09 mg (77%).
LC: 100%
MS(m/z) 528 (M+1)" 2.7 Ph(3-CI)(5-NHMe)-(R)CH{OH)C(O)-(S)Aze-Pab(OcButyl)
Prepared using O-cyclobutylhydroxylamine x HCl (16 mg; 130 pmol).
Yield: 6.24 mg (72%).
LC: 100%
MS(m/z) 500 M+1)* oo . : 2.8 Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(O)«(S)Aze-Pab(OCH,4-thiadiazole- ) Prepared using 4-(aminooxy)methyl-5-chloro-1,2,3-thiadiazole x HCI (16 mg; 79 pmol). Yield: 10.4 mg (100%).
LC: 100%
® 40
MS(m/z) 578 (M+1)* 2.9 Ph(3-CI)(5-NHMe)-(R)CH(OH)C(0)-(S)Aze-Pab(OCH,CH,0OPh(3-
CFs)
Prepared using O-[2-[3-(trifluoromethyl)phenoxy]ethyl]hydroxylamine x
HCI (21 mg; 82 pmol). Yield: 7.44 mg (65%).
LC: 96%
MS(m/z) 634 M+1)" 2.10 Ph(3-CH(5-NHMe)-(R)CH(OH)C(0)-(S)Aze-Pab(OBn(3-MeO))
Prepared using O-(3-methoxybenzyl)hydroxylamine x HCl (20 mg; 105 pmol). Yield: 5.07 mg (51%).
LC: 100%
MS(m/z) 566 (M+1)" 2.11 Ph(3-CI)(5-NHMe)-(R)CH(OH)C(O)-(S)Aze-Pab(OBn(2-Br)
Prepared using O-(2-bromobenzyl)hydroxylamine x HCl (24 mg; 101 pmol). Yield: 5.01 mg (47%).
LC: 100% :
MS(m/z) 616 (M+1)* 2.12 Ph(3-CI)(5-NHMe)-(R)CH(OH)C(0)-(S)Aze-Pab(OBn(4-Me))
Prepared using O-(4-methylbenzyl)hydroxylamine x HCI (17 mg; 98 pmol).
Yield: 6.00 mg (63%). B
LC: 100% Co ~ MS(m/z) 550 (M+1)" 'H NMR (400 MHz; CDCl): 5 7.99 (bt, 1H), 7.56 (d, 2H), 7.32 (4, 2H), 7.25 (d, 2H), 7.16 (4, 2H), 6.59 (t, 1H), 6.51 (t, 1H), 6.37 (t, 1H), 5.07 (s, 2H), 4.86 (bs, 1H), 4.84 (m, 2H), 4.76 (s, 1H), 4.44 (m, 2H), 4.03 (m, 1H), 3.70 (m, 1H), 2.75 (s, 3H), 2.60 (m, 1H), 2.35 (s, 3H), 2.34 (m, 1H).
3C NMR (100 MHz; CDCls): (carbonyl and/or amidine carbons) & 172.3, 171.1, 170.0, 151.8 or 150.9.
Example 3
Ph(3-CD)(5-NHMe)~(R)CH(OH)C(O)-(S)Aze-Pab(OMe) () Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(0)-(S)Aze-Pab(OMe, Teoc)
Ph(3-CI)(5-NHMe)«(R)CH(OH)C(O){S)Aze-Pab(Teoc) (0.043 g 0.075 mmol, see Example 1(i1) above) and O-methylhydroxylamine x HCI (0.045 g; 0.54 mmol) in THF (5 mL) were refluxed overnight. After concentration under reduced pressure, the residue was dissolved in ethyl acetate and washed with water and brine. Drying (Na,SQO,4) and removal of the solvent in vacuo afforded the sub-title compound as a colourless solid. Yield: 0.045 g (100%).
MS(m/z) 604 (M+1)", 602 (M-1) (ii) Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(0)~(S)Aze-Pab(OMe)
Trifluoroacetic acid (1.0 mL) was added to a stirred, ice/water-cooled solution of Ph(3-Cl)(5-NHMe)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe, Teoc) (45 mg; 74 pmol; see step (i) above) in methylene chloride (10 mL). The cooling bath was removed after 1.5 h. After 1 h at rt, acetonitrile was added and the solvents were carefully removed under reduced pressure. The crude product was purified using reversed-phase HPLC (acetonitrile: 0.1 M aq. ammonium acetate) to afford, after freeze drying the appropriate fractions, the title compound as a colourless solid. Yield: 19 mg (56%). . MS(m/z) 460 (M+1)7, 458 M-1)° Lo 'H NMR (300 MHz; CDCl): § 8.02 (bt, 1H), 7.60 (d, 2H),.7.32 (d, 2H), 6.64 (s, 1H), 6.56 (s, 1H), 6.40 (s, 1H), 4.87 (m, 2H), 4.8 (s, 1H), 4.47 (m, 2H), 4.06 (m, 1H), 3.91 (s, 3H), 3.70 (m, 1H), 3.0 (bs, 1H), 2.80 (s, 3H), 2.65 (m, 1H), 2.40 (m, 1H).
[ | 42 3C NMR (100 MHz; CD;OD): (carbonyl and/or amidine carbons) & 173.9, ~ 172.7, 155.1.
Example 4 Ph(3-CI)(5-NHEt)-(R)YCH(OH)C(O)-(S)Aze-Pab (i) 3,5-Dinitrobenzylalcohol
To a solution of 3,5-dinitrobenzoic acid (213.0 g, 1.00 mol) in anhydrous
THF (1500 mL) at 0°C was added borane-tetrahydrofuran complex (1.5 L of IM in THF, 1.50 mol) over 1 h. The resulting heterogeneous mixture was stirred at 0°C for 3 h and at 25°C for 18 h. The resulting homogeneous solution was quenched with H,O and concentrated in vacuo until solids were present. The solids were filtered, washed with H,O and dissolved in
EtOAc. The aqueous filtrate was extracted with EtOAc. The combined - organics were washed with aqueous NaHCO; and brine, dried (Na,SO,), filtered and concentrated in vacuo to afford 176.0 g (89%) of the sub-title compound as a solid which was used without further purification. 'H NMR (300 MHz, CD,0D) § 8.88 (m, 1H), 8.55-8.68 (m, 2H), 4.83 (s, 2H). (11) 3-Amino-5-nitrobenzyl alcohol
To a solution of 3,5-dinitrobenzyl alcohol (129.1 g, 0.65 mol; from step (i) above) in MeOH (1500 mL) at reflux was added ammonium sulfide (450 ml, 442.9 g of 20 wt% in H,0, 1.30 mol) over 45 min. The resulting heterogeneous mixture was refluxed for.2 h and stirred at 25°C for. 18 h. oo .
The solution was filtered through a pad of Celite, the filtrate was acidified with 2N HCI and the MeOH distilled off in vacuo. The remaining acidic aqueous solution was washed with Et,0 (3x) and basified with 6N NaOH.
The basic aqueous solution was extracted with Et,0 (4x). The organic extracts were dried (Na,SOy), filtered and concentrated in vacuo to afford © 95.8 g (88%) of the sub-title compound as an orange solid which was used without further purification. 'H NMR (300 MHz, CD;OD) § 7.46 (m, 1H), 7.38 (m, 1H), 6.98 (m, 1H), 4.57 (s, 2H). (1i1) 3-Chloro-5-nitrobenzyl alcohol
To a suspension of 3-amino-5-nitrobenzyl alcohol (103.8 g, 0.62 mol; from . 10 step (ii) above) in 1.0 L of 6N HCI at -5°C was added sodium nitrite (47.1 g, 0.68 mol) m H,0 (400 mL) over 45 min. The resulting solution was stired at —5°C for 1 h prior to the addition of a mixture of copper(Ilchloride (125.0 g, 0.93 mol) and copper(T)chloride (0.74 g, 0.007 mol) in 6N HCl (1.0 L) over 1 h while maintaining the temperature at less than 0°C. The resulting solution was warmed to 60-70°C for 2.5 h then cooled to room temperature and extracted with Et;O (6x). The organics were washed with brine (2x), dried (Na,SO,), filtered and concentrated in vacuo to give the crude product. Flash chromatography on silica gel eluting with Hex:EtOAc (4:1) gave 81.7 g (70%) of the sub-title compound as an off white solid. The sub-title compound could be further purified by crystallization from CH,Cl,.
Mp: 74-75 °C 'H NMR (300 MHz, CDCls) § 8.14 (s, 2H), 7.72 (s, 1H), 4.83 (d, 2H, J=7
Hz), 2.18(, 1H,J=7Hz) - : CI-MS: (M +.1) = 188. m/z :
® ha (iv) 5-Amino-3-chlorobenzyl alcohol
Method A:
To a solution of 3-chloro-5-nitrobenzyl alcohol (31.0 g, 165 mmol see step (iii) above) in EtOH (800 mL) was added platinum (IV) oxide (5 g). The suspension was stirred under one atmosphere of hydrogen for 24 h at room temperature. The reaction mixture was filtered through Celite® and the filter cake washed with EtOH. The filtrate was concentrated in vacuo to afford a brown oil which was flash chromatographed on silica gel eluting with Hex:EtOAc (1:1) to afford 12.1 g (46%) of the sub-title compound as an orange oil.
Method B:
To a solution of 3-chloro-5-nitrobenzyl alcohol (9.5 g, 50.6 mmol; see step 15s (iii) above) in EtOAc (150 mL) was added 5% sulfided Pt/C (4.7 g). The suspension was stirred under one atmosphere of hydrogen for 5 h at room temperature. The reaction mixture was filtered through Celite® and the filter cake washed with EtOAc. The filtrate was concentrated in vacuo to afford 7.6 g (95%) of the sub-title compound as a solid, which was used without further purification. 'H NMR (300 MHz, CD;OD) 5 6.68 (s, LH), 6.62 (m, 2H), 4.47 (s, 2H). (v) 3-Chloro-5-(NHAc)benzyl acetate :
To a solution of S-amino-3-chlorobenzyl alcohol (14.1 g, 89.5 mmol; see step (iv) above) in pyridine (500 mL) at 0°C was added dropwise acetic . anhydride (36.5 g, 358 mmol). The mixture was warmed to room temperature and stirred for 5 h. The mixture was concentrated in vacuo and diluted with EtOAc (300 mL). The organics were successively washed with 2N HCI (3 x 300 mL), saturated NaHCO; (200 mL) and brine (200 mL)
® 45 then dried (Na,SO,), filtered, and concentrated in vacuo to afford 20.5 g (95%) of the sub-title compound as a brown solid which was used without further purification. "HNMR (300 MHz, CDCl) § 7.62 (bs, 1H), 7.52 (s, 1H), 7.34 (s, 1H), 7.02 (s, 1H), 5.02 (s, 2H), 2.17 (s, 3H), 2.10 (s, 3H) (vi) 3-Chloro-5-(NHEt)benzyl alcohol
Lithium aluminum hydride (12.9 g, 339 mmol) was added in portions to a mechanically stirred solution of 3-chloro-5-(NHAc)benzyl acetate (20.5 g, 84.8 mmol; from step (v) above) in THF (600 mL) at 0°C. The suspension : was refluxed for 3 h, cooled to 0°C, and successively quenched with H,0 (13 mL), 3N NaOH (13 mL) and H,0 (40 mL). The solids were removed by filtration over Celite® and washed with EtOAc (500 mL). The filtrate was concentrated in vacuo to give 15.7 g (100%) of the sub-title compound as an orange oil which was used without further purification. 'H NMR (300 MHz, CDCl) 6 6.62 (s, 1H), 6.47 (s, 1H), 6.44 (s, 1H), 6.42 (s, 1H), 4.52 (s, 2H), 3.12 (q, J = 7.5 Hz, 2H), 1.25 (t, J = 7.5 Hz, 3H) (vii) 3-Chloro-5-(NHEt)benzaldehyde
Oxalyl chloride (12.0 g, 94.8 mmol). was added dropwise to a solution of dimethyl sulfoxide (14.8 g, 190 mmol) in CH,Cl, (400 mL) at 78°C. After 30 min at —78°C, a solution of 3-chloro-5-(NHEt)benzyl alcohol (15.7 g, 86.2 mmol; from step (vi) above) in CH,Cl, (250 mL) was added dropwise . over 30 min. After 30 min at —78°C, diisopropylethylamine (55.7 g, 431 mmol) was added dropwise, and the mixture was warmed to room ] temperature overnight. The mixture was successively washed with IN HCl (1.0 L), H,0 (500 mL) and brine (2 x 500 mL), dried (Na;S0,), and : concentrated in vacuo to give a brown oil. Flash chromatography on silica
0) : 46 gel eluting with Hex:EtOAc (7:1) afforded 6.40 g (40%) of the sub-title compound as a yellow solid. '"H NMR (300 MHz, CDCl;) 8 9.87 (s, 1H), 7.10 (s, 1H), 6.90 (s, 1H), 6.77 (s, 1H), 3.90 (bs, 1H), 3.20 (m, 2H), 1.25 (t,J=7.5 Hz, 3H) (viii) 3-Chloro-5-(NEt)-5-(N-trifluoroacetyl)benzaldehyde
Trifluoroacetic anhydride (9.26 g, 44.1 mmol) was added dropwise to a solution of 3-chloro-5-(INHEt)benzaldehyde (5.40 g, 29.4 mmol; from step (vii) above) and pyridine (3.49 g, 44.1 mmol) in CH,Cl, (150 mL) at 0°C.
The mixture was warmed to room temperature and stirred overnight. The mixture was successively washed with saturated Na,CO; (150 mL) and IN
HCI (150 mL), dried (Na,SO,), filtered, and concentrated in vacuo to give 7.46 g (91%) of the sub-title compound as a yellow solid which was used without further purification. : 'H NMR (300 MHz, CDCl5) § 10.0 (s, 1H), 7.91 (s, 1H), 7.62 (s, 1H), 7.50 (s, 1H), 3.80 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H) (ix) Ph(3-CD(5-NEt)(5-N-trifluoroacetyl)-CH(OTMS)CN
To a solution of 3-chloro-5-(NEt)-5-(N-trifluoroacetyl)benzal dehyde (7.46 g, 26.7 mmol; from step (viii) above) in CH,Cl, (150 mL) at 0°C was added
Zn, (425 mg, 1.34 mmol) and trimethylsilyl cyanide (2.90 g, 29.3 mmol).
The solution was stirred overnight at room temperature. The mixture was washed with HO (100 mL), dried (Na,SOy), filtered, and concentrated in vacuo to afford 9.30 .g (92%) of the sub-title compound as an orange oil Lo. which was used without further purification. 'H NMR (300 MHz, CDCl;) 8 7.58 (s, 1H), 7.29 (s, LH), 7.24 (s, 1H), 5.52 (s, 1H), 3.80 (q,/="7.5 Hz, 2H), 1.20 (t, = 7.5 Hz, 3H), 0.30 (s, 9H)
® 47 (x) Ph(3-CI)(5-NHE%)-(R.S)CH(OH)C(O)OH
Ph(3-CI)(5-NEt)(5-N-trifluoroacety) CHOOTMS)CN (1.40 g, 3.69 mmol; } from step (ix) above) was refluxed in concentrated HCI (10 mL) for 6 h at which time, the mixture was concentrated in vacuo to give a brown solid.
Flash chromatography on silica gel eluting with CHCl;:MeOH:concentrated
NH,OH (6:3:1) afforded the ammonium salt of the sub-title compound which was dissolved mn H,0, acidified (pH~5) with IM HC] and extracted with EtOAc (3 x 15 mL). The. combined organics were dried (Na,SO,), filtered, and concentrated in vacuo to afford 540 mg (64%) of the sub-title compound as a brown solid. 'H NMR (300 MHz, CD30D) 8 6.69 (s, 1H), 6.64 (s, 1H), 6.54 (s, 1H), 5.03 (s, 1H), 3.10 (q, J = 7.1 Hz, 2H), 1.21 (t, J = 7.2 Hz, 3H) (xi) Ph(3-CD)(5-NHEt)-(R)CH(OH)C(O)OH (a) and Ph(3-Cl)(5-NHEf)- (S)CH(OAC)C(O)OH (b)
A mixture of Ph(3-CI)(5-NHE!)-(R,S)CH(OH)C(O)OH (540 mg, 2.36 mmol; from step (x) above) and Lipase PS “Amano” (280 mg) in vinyl acetate (15 mL) and MTBE (15 mL) was heated at reflux for 22 h. The reaction mixture was filtered through Celite® and the filter cake washed with EtOAc (100 mL).
The filtrate was concentrated in vacuo and subjected to flash chromatography on silica gel eluting with CHCl;:MeOH:concentrated NH,OH (6:3:1) yielding the ammonium salts of the sub-title compounds (a) and (b). The ammonium salt of the sub-title compound (a) was taken up in EtOAc (10 mL) and . | neutralized with 2M HCI in Et;0 (0.65 mL). Water (10 mL) was added, and = the layers were separated. The aqueous layer was extracted with EtOAc (2 x 20 ml), and the combined organic extracts were dried (Na,SO,), filtered, and concentrated in vacuo to afford 260 mg (48%) of the subtitle compound (a) as
® 48 a white solid. The ammonium salt of the sub-title compound (b) (260 mg, 46%) was used without further manipulation or characterization.
For sub-title compound (a): "HNMR (300 MHz, CD;0D) § 6.69 (s, 1H), 6.64 (s, 1H), 6.54 (s, 1H), 5.03 (s, 1H), 3.10 (q, J= 7.1 Hz, 2H), 1.21 (t, J= 7.2 Hz, 3H)
For sub-title compound (b): 'H NMR (300 MHz, CD;0D) § 6.69 (s, 1H), 6.65 (s, 1H), 6.56 (s, 1H), 5.70 (s, 1H), 3.08 (q, J= 7.1 Hz, 2H), 2.14 (s, 3H), 1.20 (t, J= 7.2 Hz, 3H) (xii) Ph(3-CI}5-NEt-(RYCH(OH)C(O)(S)Aze-Pab(Teoc) :
To a solution of Ph(3-CI)(5-NHE)-(R)CH(OH)C(O)OH (260 mg, 1.22 mmol; sub-title compound (a) from step (xi) above) and H-(:S)Aze-Pab(Teoc) (602 mg, 1.34 mmol) in DMF (10 mL) at 0°C was added PyBOP (698 mg, 1.34 mmol) and collidine (517 mg, 4.27 mmol). The solution was stirred at 0°C for 2 h and then warmed to room temperature and stirred overnight. The mixture was . partitioned with EtOAc (3 x 50 mL) and H,O (50 mL). The combined organics were dried (Na,SO,), filtered, and concentrated in vacuo. Flash chromatography on silica gel eluting with CHCl;:MeOH (20:1) followed by rechromatography (2x) eluting with EtOAc:EtOH (20:1) afforded 157 mg (22%) of the sub-title compound as a white solid.
Mp: 95-100°C
R¢=0.40 (15:1 CHCl3:MeOH) © 25 'H NMR (300 MHz, CD;0D, mixture of rotamers) § 7.80 (d, J = 8.2 Hz, 2H), 7.41 (d, J=8.2 Hz, 2H), 6.63 (s, 1H), 6.57 (s, 1H), 6.53 (s, 1H), 5.10- - .5.15 (m, 1H), 5.00 (s, 1H), 4.74-4.81 (m, 1H), 4.20-4.52 (m, SH), 3.90-4.10 (m, 2H), 3.07 (q, J = 7.2 Hz, 2H), 2.44-2.68 (m, 1H), 2.14-2.33 (m, 1H), 1.21 (t,J= 7.1 Hz, 3H), 1.08 (t,J= 8.6 Hz, 2H), 0.08 (s, 9H) :
API-MS (M+ 1)=588 m/z :
® 49 (xiii) Ph(3-Cl)(5-NHEt)-(R)CH(OH)C(O)-(S)Aze-Pab
TFA (4.0 mL) was added to a solution of Ph(3-Cl)(5-NHEt)-(R)CH(OH)C(0)- (S)Aze-Pab(Teoc) (0.090 g, 0.15 mmol; from step (xii) above) in DCM (2 mL) at rt. The reaction mixture was stirred for 15 minutes. The solvent was evaporated without heating. The product was dissolved in acteonitrile and water (1:5) and freeze-dried to yield 70 mg (68%) of the title compound. 'H NMR (500 MHz; D,0): § 7.70-7.12 (m, 7H), 5.23-4.72 (m, 2H), 4.40- 3.92 (m, 5H), 3.24 (m, 2H), 2.55 (m, 1H), 2.10 (m, 1H), 1.14 (m, 3H)
LC-MS (m/z) 444 M+1)"
Example 5
Ph(3-C1)(5-NHAC¢)-(R)YCH(OH)C(O)-(S)Aze-Pab oo (i) Ph(3-CI)(5-NHAc)-(R)CH(OH)C(O)OH
A solution of Ph(3-Cl)(5-NH,)-(R)CH(OH)C(O)OH (1.5 g, 7.44 mmol; see international patent application WO 00/42059) in pyridine (100 mL) at 0°C was treated with acetic anhydride (0.77 mL, 0.84 g, 8.18 mmol). After 30 min, additional acetic anhydride (0.35 mL) was added and the reaction was warmed to 25°C. After 1 h, a third aliquot of acetic anhydride (0.17 mL) was added and the reaction was stirred at 25°C for 18 h. The solution was concentrated in vacuo, the residue dried, dissolved in MeOH, made basic with 2 N NaOH and stirred for 3 h. The solution was neutralized with excess Amberlite CG-50 and filtered through a pad of Celite. The organics 3 : were concentrated in vacuo and flash chromatographed on silica gel eluting with CHCl;:MeOH:concentrated NH,OH (7:2.5:0.5) to afford 1.5 g (83%) ' of the ammonium salt of the sub-title compound as a solid with a chiral purity of 89% ee by chiral HPLC analysis.
® 50
Due to the low chiral purity of the sub-title compound, the corresponding salt was neutralized with Amberlite CG-50 and subjected to enzymatic resolution (0.3 g Lipase PS Amano; 20 mL MTBE; 20 mL vinyl acetate; 55°C; 18 h). Filtration through Celite followed by concentration and flash ) chromatography on silica gel eluting with CHCl;:MeOH:concentrated
NH,OH (6:3:1) afforded 1.0 g of the ammonium salt of the sub-title compound as a crushable foam. The sub-title compound was obtained as a solid by partitioning the corresponding ammonium salt between 1 M HCI and EtOAc and concentrating the organics in vacuo.
Mp: 155-157°C
Rs= 0.25 (6:3:1 CHCl;:MeOH:concentrated NH,OH) 'H NMR (300 MHz, CD;0D) & 7.76 (m, 1H), 7.49 (m, 1H), 7.22 (s, 1H), 5.12 (s, 1H), 2.13 (s, 3H). °C NMR (75 MHz, CD;0D) & 175.5, 172.0, 143.6, 141.4, 135.5, 123.2, 120.5, 117.6, 73.5, 24.0.
API-MS: (M + 1) = 244 m/z
HPLC Analysis: 96.3%, 95.7% ee, Chiralcel OD Column (92:8:0.5°
Hex:EtOH: TFA mobile phase). [o}p®=-99.4°(c=10, MeOH) (11) Ph(3-CD(5-NHAc)-(R)CH(OH)C(0O)-(S)Aze-Pab(Teoc)
To a mixture of Ph(3-Cl)(5-NHAc)-(R)CH(OH)C(O)OH (0.25 g, 1.01 mmol; see step (i) above) and H-(S)Aze-Pab(Teoc) (0.40 g, 1.06 mmol, see international patent application WO 00/42059) in DMF (15 mL) at 0°C was added collidine (0.27 g, 2.22 mmol) and PyBOP (0.58 g, 1.11 mmol).
The solution was stirred at 0°C for 2 h, warmed to 25°C and stirred for 18h then concentrated in vacuo. The residue was dissolved in EtOAc and washed with H,O and brine. The organics were dried (Na,SO,), filtered and concentrated in vacuo. Extensive flash chromatography (3x) on silica gel
® 51 eluting first with CHCI;:EtOH (95:5) then second with
CH,Cl;:MeOH:concentrated = NH,OH (94:5:1) and last with
CH,Cl;:MeOH:concentrated NH4OH (88.5:10:1.5) gave 0.40 g (66%) of the ) sub-title compound as a crushable foam. - 3
Mp: 65-72°C ‘R= 0.45 (9:1 CH,Cl;:MeOH) 'H NMR (300 MHz, CD;OD, mixture of rotamers) § 7.79 (d, 2H, J= 9 Hz), 7.68 (m, 1H), 7.35-7.53 (m, 3H), 7.18 and 7.15 (m, 1H), 5.18 and 4.79. (m, 1H), 5.14 and 5.09 (s, 1H), 3.93-4.55 (m, 6H), 2.05-2.78 (m, 2H), 2.12 (s, 3H), 1.03-1.13 (m, 2H), 0.08 (s, 9H).
API-MS: M + 1) = 602 m/z (iit) Ph(3-Cl)(5-NHACc)-(R)CH(OH)C(O)-(S)Aze-Pab
To a solution of Ph(3-CI)}(5-NHAc)-(R)CH(OH)C(O)-(S)Aze-Pab(Teoc) (0.11 g, 0.18 mmol; see step (ii) above) in 2 mL of CH,Cl, was added 2 mL of TFA. The mixture was allowed to react for 4h and subsequently evaporated. The crude product was purified using PHPLC (C8 column, 50 x 250 mm, gradient: 0 to 50% CH;CN, 60 ml/min). After evaporation the residue was freeze dried from water-acetic acid. Yield: 95 mg of the title compound as an acetate salt (99%). 'H NMR (500 MHz, D,0, mixture of rotamers): 8 7.66 (m, 2H), 7.50 (m, 1H minor rotamer), 7.45-7.35 (m, 3H), 7.22 (m, 1H), 7.07 (m, 1H minor rotamer), 5.25 (m, 1H rotamer), 5.15-5.10 (m, 2H rotamer) 4.84 (m, 1H . : rotamer), 4.55-4.45 (m, 2H rotamer), 4.41 (m, 1H rotamer), 4.28 (d, 1H . rotamer), 4.18-3.95 (m, 2H rotamer), 2.78 (m, 1H rotamer), 2.58 (m, 1H ) rotamer), 2.35-2.16 (m, 1H), 2.13 (s, 3H rotamer), 2.11 (s, 3H rotamer), 1.92 (s, 3H).
® 52 “C NMR (125 MHz, D,0): § 173.9, 173.1, 173.0, 172.80, 172.76, 172.6, 166.6, 166.5.
MS: (M+1) 458 m/z
Example 6
Ph(3-Cl1)(5-NHAc)-(R)CH(OH)C(O)-(S)Aze-Pab(0QiPr) : : - A mixture of Ph(3-CI)(5-NHACc)~(R)CH(OH)C(0)-(S)Aze-Pab(Teoc) (60 mg, 0.10 mmol; see Example 5(ii) above) and H,NOiPr x HCI (70 mg, 0.63 mmol) in THF (5 mL) was heated to 60°C overnight. The solvent was evaporated and the crude was partitioned between water and EtOAc. The water phase was extracted with EtOAc and the organic layers were dried . (Na;SO,) and concentrated to give 65 mg (100%) of the title compound.
The crude material was dissolved in DCM (2 mL) at rt, TFA (2.0 mL) was added and the reaction mixture was stirred for 1 hour. The solvent was evaporated without heating and the crude was partitioned between water and EtOAc. The water phase was extracted with EtOAc and the organic phase was dried (Na,SO,4) and concentrated. The crude was subjected to flash chromatography using DCM:MeOH (95:5) as eluent. The product was : further purified with preparative RPLC (CH;CN:0.1M NH4OAc-buffered, 0-50%), the fractions of interest were concentrated and the ‘product was freeze-dried to yield 50 mg (94%) of the title compound. 'H NMR (400 MHz; CD30D): 6 7.70-7.12 (m, 7H), 5.20-4.72 (m, 2H), 4.48-3.92 (m, 5H), 2.73-2.11 (m, 2H), 2.10 (s, 3H), 1.26 (s, 3H), 1.24 (s, 3H).
C NMR (100 MHz, CD30D): (carbonyl and/or amidine carbons) § 172.3; } . 171.5; 170.6
LC-MS (m/z) 517 (M+1)* : ’
® © 53
Example 7
The title compounds of Examples 1, 4 and 5 were tested in Test A above and were found to exhibit an ICspTT value of less than 0.02 uM. . 5 Example 8
The title compounds of Examples 1, 4 and 5 were tested in Test D above ‘and were found to exhibit an ICsoAPTT value of less than 1 uM.
Example 9
Title compounds of Examples 2 and 3 were tested in Test G above and were found to be converted to the corresponding active inhibitor (free amidine) m liver microsomes from humans and rats.
Example 10
The title compounds of Examples 3 and 6 were tested in Test E above and were found to exhibit oral and/or parenteral bioavailability in the rat as the corresponding active inhibitor (free amidine).
Abbreviations
Ac = acetyl
AcOH = acetic acid
API = atmospheric pressure ionisation (in relation to MS) :
AUC = area under the curve
Aze = azetidine-2-carboxylate
AzeOH = azetidine-2-carboxylic acid : BSA = bovine serum albumin
Bn a. benzyl
Bu = butyl
Bzl = benzyl : 36 CI = chemical ionisation (in relation to MS)
® : 54 d = day(s)
DCC = dicyclohexyl carbodiimide
DCM = dichloromethane
DIPEA = diisopropylethylamine
DMAP = 4-(N,N-dimethyl amino) pyridine
DMF = dimethylformamide
DMSO = dimethylsulfoxide
EDC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
Et = ethyl
Et,O = diethyl ether ether = diethyl ether
EtOAc = ethyl acetate
EtOH = ethanol h = . hour(s) :
HATU = O-(azabenzotriazol-1-y1)-N,N,N’ ,N’-tetramethyluronium hexafluorophosphate
HBTU = [NNN N’-tetramethyl-O-(benzotriazol- 1-yljuronium hexafluorophosphate]
HCl = hydrochloric acid
HCl(g) = hydrogen chloride gas :
Hex = hexanes
HOAc = acetic acid
HPLC = high performance liquid chromatography 2s LC = liquid chromatography
Me. =. methyl CL } .
MeOH = methanol
Mp = melting point : B
MS = mass spectroscopy
MTBE = methyl tert-butyl ether
® 55
NADH = nicotinamide adenine dinucleotide, reduced form
NADPH = nicotinamide adenine dinucleotide phosphate, reduced form : NIH = National Institute of Health (US) } 5 NHU = National Institute of Health units " Pab = para-amidinobenzylamino "H-Pab = para-amidinobenzylamine
Ph = phenyl
PHPLC = preparative high performance liquid chromatography
Pr = propyl
PyBOP = (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate :
QF = tetrabutylammonium fluoride
RPLC = reverse phase high performance liquid chromatography rt : = room temperature
SOPs = standard operating procedures
TBTU = [N,N,N ,N’-tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate]
TEA = triethylamine :
Teoc = 2-(trimethylsilyl)ethoxycarbonyl : ~ TFA = trifluoroacetic acid
THF = tetrahydrofuran
THP ma tetrahydropyranyl
TLC = thin layer chromatography 2s TMSCN = trimethylsilyl cyanide . Zz = benzyloxycarbonyl :
Prefixes n, s, i and ¢ have their usual meanings: normal, secondary, iso and tertiary. The prefix ¢ means cyclo.
Claims (1)
- o 56 Claims1.. A compound of formula I, 0 Y HO i | NH a X | Na oO Ci NH A5 . wherein R! represents C(O)CH; or C, 3 alkyl; and Y represents -CH,- or -(CH,),-, or a pharmaceutically-acceptable derivative thereof.2. A compound as claimed in Claim 1, wherein Y represents -CH,-.3. A compound as claimed in Claim 1 or Claim 2, wherein R' represents C(O)CHj, methyl or ethyl. -4. A compound as claimed in any one of the preceding claims which is . Ph(3-CI)(5-NHMe)-CH(OH)C(O)-Aze-Pab or a pharmaceutically- acceptable derivative thereof.20 .5. A compound as claimed in any one of Claims 1 to 3 which is Ph(3- CI)(5-NHACc)-CH(OH)C(O)-Aze-Pab or a pharmaceutically-acceptable derivative thereof. NE }® 576. A pharmaceutically acceptable derivative of a compound of formula I as defined in Claim 1, which derivative compound is a compound of formula Ia, . Q 2 NH, la oe Cl NH : ! wherein R? represents OR® or C(O)OR%; R? represents H, C,.;0 alkyl, Cy; alkylaryl or C,; alkyloxyaryl (the alkyl parts of which latter two groups are optionally interrupted by one or more oxygen atoms, and the aryl parts of which latter two groups are optionally substituted by one or more substituents selected from halo, phenyl, methyl or methoxy, which latter three groups are also optionally substituted by one or more halo substituents); : R* represents Cy; alkyl (which latter group is optionally interrupted by one : or more oxygen atoms), or Cy alkylaryl or C,; alkyloxyaryl (the alkyl parts of which latter two groups are optionally interrupted by one or more oxygen atoms, and the aryl parts of which latter two groups are optionally substituted by one or more substituents selected from halo, phenyl, methyl or methoxy, which latter three groups are also optionally substituted by one or more halo substituents); and R' and Y are as defined in Claim 1, | I or a pharmaceutically-acceptable derivative thereof.7. A compound as claimed in Claim 6, wherein R? represents OR’.8. A compound as claimed in Claim 7, wherein R’ represents: H; unsubstituted, linear, branched or cyclic C,; alkyl; C;.; alkyloxyphenyl, the phenyl group of which is optionally substituted by one or more substituents as defined in Claim 6; or C,.; alkylaryl, wherein the aryl group is phenyl, ’ pyridinyl, isoxazolyl or thiadiazolyl, which latter four groups are optionally } substituted by one or more substituents as defined in Claim 6.9. A compound as claimed in Claim 8, wherein R® represents: linear C4 alkyl, or cyclic Cj alkyl; or methylaryl, wherein the aryl group is phenyl or isoxazolyl, which latter two groups are optionally substituted in the aryl part by one substituent selected from methoxy, methyl and bromo.10. A compound as claimed in Claim 9, wherein R® represents methyl, ethyl, i-propyl, cyclohexyl, 4-methylbenzyl, 3-methoxybenzyl, 2- bromobenzyl or 5-methyl-3-isoxazolyl.11. A compound as claimed in any one of the preceding claims, wherein the 0 hs cl NH . Ri20 . R fragment is in the R-configuration.12. A compound as claimed in any one of the preceding claims, wherein the® 59 . ’ Y . Ua x) . 0 fragment is in the S-configuration. :13. A compound as claimed in Claim 1 which is Ph(3-CI)(5-NHMe)- (R)CH(OH)C(O)-(S)Aze-Pab or a pharmaceutically acceptable derivative thereof.14. A compound as claimed in Claim 1 which is Ph(3-CI)(5-NHAc)- - (R)CH(OH)C(O)-(S)Aze-Pab or a pharmaceutically acceptable derivative thereof.15. A pharmaceutical formulation including a compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, mm admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.16. A compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, for use as a pharmaceutical.17. A compound as defined in any one of Claims 1 to 14, or a : pharmaceutically acceptable derivative thereof, for use in the treatment of a _ condition where inhibition of thrombin is required. -18. A compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative theréof, for use in the treatment of a condition where anticoagulant therapy is indicated.60 PCT/SE01/0175119. A compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, for use in the treatment of thrombosis.20. A compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, for use as an anticoagulant.21. The use of a compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, as active ingredient for the manufacture of a medicament for the treatment of a condition wherein inhibition of thrombin is required.22. The use of a compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, as active ingredient for the manufacture of a medicament for the treatment of a condition where anticoagulant therapy is indicated.23. The use as claimed in Claim 21 or Claim 22, wherein the condition is thrombosis.24. The use as claimed in Claim 21 or Claim 22, wherein the condition is hypercoagulability in blood and/or tissues.25. The use of a compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, as active ingredient for the manufacture of an anticoagulant.26. A substance or composition for use in a method of treatment of a condition where inhibition of thrombin is required, said substance or composition AMENDED SHEET61 PCT/SE01/01751 comprising a compound as defined in any one of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, and said method comprising administration of a therapeutically effective amount of said substance or composition to a person suffering from, or susceptible to, such a condition.27. A substance or composition for use in a method of treatment of a condition where anticoagulant therapy is indicated, said substance or composition comprising a compound as defined in any ome of Claims 1 to 14, or a pharmaceutically acceptable derivative thereof, and said method comprising administration of a therapeutically effective amount of said substance or composition to a person suffering from, or susceptible to, such a condition.28. A substance or composition for use in a method of treatment as claimed in Claim 26 or Claim 27, wherein the condition is thrombosis.29. A substance or composition for use in a method of treatment as claimed in Claim 26 or Claim 27, wherein the condition is hypercoagulability in blood and/or tissues.30. A process for the preparation of a compound of formula I, as defined in Claim 1 which comprises: (i) the coupling of a compound of formula II00. H OH il Cl NH Ly R wherein R! is as defined in Claim 1, with a compound of formula III, AMENDED SHEET° i —Y © NH N H Hl 7 : H NH, So 8) wherein Y is as defined in Claim 1; : (11) the coupling of a compound of formula IV, i Y HO I Oo cl NH R1 wherein R' and Y are as defined in Claim 1, with para- amidinobenzylamine; or (i11) deprotection of a protected derivative of a compound as defined in Claim1. :31. A compound of formula II as defined in Claim 30 or a protected : derivative thereof.32. A compound as claimed in Claim 31 which is Ph(3-CI)(5-NHMe)- CH(OH)C(O)OH or a protected derivative thereof, or Ph(3-CI)}(5-NHAc)- CH(OH)C(O)OH or a protected derivative thereof.33. A compound of formula IV, as defined in Claim 30, or a protected derivative thereof.K | ;34. A compound as claimed in Claim 33 which is Ph(3-Cl)(5-NHMe)- CH(OH)C(O)-Aze-OH or a protected derivative thereof, or Ph(3-Cl)(5- : NHMe)-CH(OH)C(0)-Aze-OH or a protected derivative thereof.35. A process for the preparation of a compound of formula Ia as defined mn Claim 6, which comprises: (a) the coupling of a compound of formula II as defined in Claim 30 with a compound of formula X11, —Y N—R? N H / XII H NH, oO wherein Y is as defined in Claim 1 and R? is as defined in Claim 6; (b) the coupling of a compound of formula IV, as defined in Claim 30, with" a compound of formula XIII, N—R? HN / Xill 2 NH, wherein R? is as defined in Claim 6; . (c) for compounds of formula Ia in which R? represents OH, reaction of a corresponding compound of formula XIV,® ” ° y HO [ N § Lr XIV 4 : Cl NH : . . R1 wherein R' and Y are as defined in Claim 1, with hydroxylamine; (d) for compounds of formula Ia in which R? represents OR? reaction of a compound of formula XV, 0 HO HE K XV S NH, 0) Cl NH R1 wherein R* represents -CH,CH,-Si(CH3); or benzyl, and R' and Y are as defined in Claim 1, or a tautomer thereof, with a compound of formula XVI, R’ONH, XVI wherein R’ is as defined in Claim 6, or an acid addition salt thereof, followed by removal of the —C(O)OR* group; }65 PCT/SE01/01751 (e) for compounds of formula Ja in which R? represents COOR®, reaction of a corresponding compound of formula I, as defined in Claim 1, with a compound of formula XVII, | : L'COOR* XVI “wherein L' represents a leaving group, and R* is as defined in Claim 6; or (f) for compounds of formula Ia in which R? represents OCH; or OCH,CHs;, reaction of a corresponding compound of formula Ia in which R? represents OH with dimethylsulfate or diethylsulfate, respectively.36. A compound of formula XIV, as defined in Claim 35, or a protected derivative thereof.37. A compound of formula XV , as defined in Claim 35, or a protected derivative thereof. )38. A compound as claimed in Claim 37 which is Ph(3-CI)(5-NHMe)- CH(OH)C(O)-Aze-Pab(Teoc) or a protected derivative thereof, or Ph(3- : CI)(5-NHMe)-CH(OH)C(O)-Aze-Pab(Teoc) or a protected derivative thereof.39. A compound according to any one of Claims 1 to 20, 31 to 34, or 36 to 38, substantially as herein described and illustrated.40. Use according to any one of Claims 21 to 25, substantially as herein described and illustrated. AMENDED SHEET66 PCT/SE01/0175141. A substance or composition for use in a method of treatment according to any one of Claims 26 to 29, substantially as herein described and illustrated.42. A process according to Claim 30 or Claim 35, substantially as herein described and illustrated.43. A new compound, a new use of a compound as claimed in any one of Claims 1 to 14, a substance or composition for a new use in a method of treatment, or a new process for the preparation of a compound, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002922A SE0002922D0 (en) | 2000-08-16 | 2000-08-16 | Pharmaceutically useful compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200300258B true ZA200300258B (en) | 2004-05-20 |
Family
ID=20280710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200300258A ZA200300258B (en) | 2000-08-16 | 2003-01-09 | New amidino derivatives and their use as thrombin inhibitors. |
Country Status (2)
Country | Link |
---|---|
SE (1) | SE0002922D0 (en) |
ZA (1) | ZA200300258B (en) |
-
2000
- 2000-08-16 SE SE0002922A patent/SE0002922D0/en unknown
-
2003
- 2003-01-09 ZA ZA200300258A patent/ZA200300258B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SE0002922D0 (en) | 2000-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070249578A1 (en) | New amidino derivatives and their use as thrombin inhibitors | |
EP1036061B1 (en) | New compounds | |
AU764121B2 (en) | New amidinobenzylamine derivatives and their use as thrombin inhibitors | |
CA2415383C (en) | New amidino derivatives and their use as thrombin inhibitors | |
AU2001280395A1 (en) | New amidino derivatives and their use as thrombin inhibitors | |
US6433186B1 (en) | Amidino derivatives and their use as thormbin inhibitors | |
KR100928285B1 (en) | Novel mandelic acid derivatives and their use as thrombin inhibitors | |
RU2341516C2 (en) | Almond acid derivatives and their use as thrombin inhibitor | |
ZA200300258B (en) | New amidino derivatives and their use as thrombin inhibitors. | |
AU2002324410A1 (en) | New mandelic acid derivatives and their use as thrombin inhibitors | |
JP2008546684A (en) | Thrombin inhibitory 2-oxo-1,2,5,6-tetrahydropyridine derivative | |
KR100483869B1 (en) | New Amino Acid Derivatives and Their Use as Thrombin Inhibitors |